Employing expertise from UNC’s School of Medicine, the Gillings School of Global Public Health, and the Eshelman School of Pharmacy, the Rapidly Emerging Antiviral Drug Development Initiative (READDI), an open-science, nonprofit drug research and development organization, is creating “self-stable” antiviral therapeutics for each of the main virus families. The therapeutics will be poised for rapid development against new pandemic viruses as they emerge.
READDI is the evolution of an interdisciplinary research known as the Infectious Disease Discovery Program at UNC (ID3@UNC), which was awarded funding through the Creativity Hubs initiative in 2019. Having a team already in place allowed the group to respond nimbly and quickly to the coronavirus outbreak and identify more partners to help in the fight against it.
Master of Ceremonies:
Matt Tremblay | Lead, Drug Discovery, Scripps Research Translational Institute and Chief Operating Officer, Scripps Research
Featured Speakers:
-Nat Moorman
-Kenneth Pearce
-Natalia Summerville